Daiichi Sankyo Company, Limited announced that the United States Court of Appeals for the Federal Circuit has affirmed the U.S. District Court decision in patent litigation against Mylan, upholding the validity of the Daiichi Sankyo U.S. patent covering Benicar, Benicar HCT, and AZOR. Daiichi Sankyo initiated litigation against Mylan in response to Abbreviated New Drug Applications filed by Mylan seeking to market generic versions of Benicar, Benicar HCT and AZOR before the expiration of the Daiichi Sankyo patent, which expires in 2016.
The litigation involves the Daiichi Sankyo U.S. patent covering olmesartan medoxomil, the active ingredient in Benicar, Benicar HCT, and AZOR. Independently developed by Daiichi Sankyo, olmesartan medoxomil is an angiotensin II receptor antagonist that suppresses vasoconstriction to control blood pressure. Products containing olmesartan medoxomil are marketed in more than 60 countries as treatments for hypertension.
Date: September 10, 2010
Source: Daiichi Sankyo Company, Limited
Filed Under: Drug Discovery
